Adjudicating Mild Cognitive Impairment Due to Alzheimer’s Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial

Schneider, L. S., Bennett, D. A., Farlow, M. R., Peskind, E. R., Raskind, M. A., Sano, M., Stern, Y., Haneline, S., Welsh-Bohmer, K. A., O’Neil, J., Walter, R., Maresca, S., Culp, M., Alexander, R., Saunders, A. M., Burns, D. K., & Chiang, C. (2022). Adjudicating Mild Cognitive Impairment Due to Alzheimer’s Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial. The Journal of Prevention of Alzheimer’s Disease. https://doi.org/10.14283/jpad.2022.72
Authors:
Lon S. Schneider
D.A. Bennett
M.R. Farlow
E.R. Peskind
M.A. Raskind
M. Sano
Y. Stern
S. Haneline
K.A. Welsh-Bohmer
J. O’Neil
R. Walter
S. Maresca
M. Culp
R. Alexander
A.M. Saunders
D.K. Burns
C. Chiang
Affiliated Authors:
Y. Stern
Columbia Affiliation:
Author Keywords:
mild cognitive impairment
adjudication
methodology
randomized clinical trial
delay of onset of mci due to ad
pioglitazone
elink
Publication Type:
Article
Unique ID:
10.14283/jpad.2022.72
PMID:
36281666
DOI:
10.14283/jpad.2022.72
Journal:
Journal of Prevention of Alzheimer's Disease
Publication Date:
Data Source:
Scopus
Source Link:
View Scopus Record
View Web of Science Record

Record Created: